During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

Q4 2024 Management View CEO Tim Herbert highlighted milestones in 2024, including surpassing 90,000 patients treated with Inspire therapy, FDA approval of the Inspire V neurostimulator, and achieving ...

Inspire Medical Systems ( INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, ...

In a highly anticipated conference call, Inspire Medical Systems reported an impressive fourth quarter and full year 2024 ...

the FDA approval of the Inspire V neurostimulator, and achieving full-year profitability for the first time. He also underscored recent organizational changes aimed at driving future growth ...

Inspire Medical Systems Inc (INSP) reports a 25% revenue increase and outlines future growth strategies amid DOJ ...

Q4 2024 Earnings Call Transcript February 10, 2025 Inspire Medical Systems, Inc. beats earnings expectations. Reported EPS is ...

Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results topping the market’s revenue ...

The company activated 72 new centers in the U.S. and initiated the soft launch of the new Inspire V neurostimulator with over 40 implants completed. Inspire also provided revenue guidance for 2025 ...

It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by ...

The company further announced a soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S. and implemented a new organizational structure aimed at ...

The Zacks Consensus Estimate is pegged at $949.4 million. During the fourth quarter of 2024, Inspire Medical initiated the soft launch of the Inspire V neurostimulator, with over 40 implants completed ...